Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

SUMO1/sentrin Specific Protease 6 (SENP6) Peptide

SENP6 Reactivity: Human Host: Synthetic BP, WB
Catalog No. ABIN983536

Quick Overview for SUMO1/sentrin Specific Protease 6 (SENP6) Peptide (ABIN983536)

Target

SENP6 (SUMO1/sentrin Specific Protease 6 (SENP6))

Origin

Human

Source

  • 5
Synthetic

Application

Blocking Peptide (BP), Western Blotting (WB)
  • Characteristics

    This is a synthetic peptide designed for use in combination with anti-SENP6 antibody (Catalog #: ARP50600_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.

    Purification

    Purified
  • Application Notes

    Each Investigator should determine their own optimal working dilution for specific applications.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Concentration

    1 mg/mL

    Buffer

    Final peptide concentration is 1 mg/mL in PBS.

    Handling Advice

    Avoid repeated freeze-thaw cycles.

    Storage

    -20 °C

    Storage Comment

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target

    SENP6 (SUMO1/sentrin Specific Protease 6 (SENP6))

    Background

    SENP6 is a UBL-specific protease that deconjugates SUMO1, SUMO2 and SUMO3 from targeted proteins. It does not seem to be involved in the processing of full-length SUMO proteins to their mature forms. SENP6 deconjugates SUMO1 from RXRA, leading to transcriptional activation. It may act preferentially on substrates containing 3 or more SUMO2 or SUMO3 moieties.Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1, MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex, as well as in stabilization of I-kappa-B-alpha (NFKBIA, MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL precursors need to be removed by UBL-specific proteases, such as SENP6, prior to their conjugation to target proteins (Kim et al., 2000 [PubMed 10799485]).[supplied by OMIM].

    Alias Symbols: FLJ11355, FLJ11887, KIAA0389, KIAA0797, SSP1, SUSP1

    Protein Interaction Partner: ARNT,SUMO1

    Protein Size: 1105

    Molecular Weight

    125 kDa

    Gene ID

    26054

    NCBI Accession

    NM_001100409, NP_001093879

    UniProt

    Q9GZR1
You are here:
Chat with us!